Recognition of Rous sarcoma virus-induced tumor antigens by cytotoxic T lymphocytes (CTL): studies on specificity of killing by CTL employing H-2 congenic and recombinant mouse tumor cells.
The specificities of cytotoxic T lymphocytes (CTL) were studied for the analysis of CTL against tumor-specific cell surface antigen(s) (TSSA) of non-virus-producing tumor cells induced by the Schmidt-Ruppin strain of Rous sarcoma virus (SR-RSV) in B10 congenic and recombinant mice. Eight CTL clones were established from immune spleen cells of B10.A(5R) mice. These clones demonstrated six patterns of cytotoxic reactivity in vitro: Two clones showed H-2 restriction in tumor cell lysis. Two other clones had the capacity to lyse syngeneic, H-2K-compatible B10 and H-2-incompatible B10.A(4R) tumor cells, but not YAC-1 cells. One clone had cytotoxic activity against syngeneic, H-2D-compatible B10.D2 tumor cells and YAC-1 cells, but not against H-2-incompatible tumor cells. One clone had cytotoxic activity against syngeneic and YAC-1 tumor cells, but not against either H-2-compatible or H-2-incompatible tumor cells. One clone had lytic activity to syngeneic, H-2-compatible, H-2-incompatible, and YAC-1 tumor cells. Another clone killed H-2-incompatible B10.A(4R) tumor and YAC-1 cells, but not syngeneic or H-2-compatible tumor cells. All these clones strongly expressed surface Thy-1.2 antigens, whereas the expression of Lyt-1.2 and Lyt-2.2 antigens was different from clone to clone. These results demonstrate heterogeneity of both lytic specificity and phenotype of CTL against RSV-induced mouse tumor cells, suggesting the existence of multiple antigenic sites on the RSV TSSA recognized by CTL populations.
D000818:Animals; D000945:Antigens, Differentiation, T-Lymphocyte; D015478:Antigens, Heterophile / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D000954:Antigens, Surface / Q000276:immunology; D000956:Antigens, Viral / Q000008:administration & dosage* / Q000276:immunology; D001358:Avian Sarcoma Viruses / Q000276:immunology*; D002460:Cell Line; D002999:Clone Cells; D003165:Complement System Proteins / Q000502:physiology; D003602:Cytotoxicity, Immunologic; D000939:Epitopes / Q000276:immunology; D005260:Female; D006183:H-2 Antigens / Q000276:immunology*; D007376:Interleukin-2 / Q000276:immunology; D007518:Isoantibodies / Q000008:administration & dosage / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D010641:Phenotype; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D013997:Time Factors
D000945:Antigens, Differentiation, T-Lymphocyte; D015478:Antigens, Heterophile; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D000956:Antigens, Viral; D000939:Epitopes; D006183:H-2 Antigens; D007376:Interleukin-2; D007518:Isoantibodies; C035678:anti-Thy antibody; D003165:Complement System Proteins